Conclusions SC complicated by psychiatric symptoms may be difficult to manage as both physical and psychiatric symptoms require on-going collaborative assessment and treatment within paediatric services and CAMHS.

**G57(P)** TO PRESENT A CASE OF PERINATAL ARTERIAL ISCHAEMIC STROKE (PAIS) THAT PRESENTED WITH RECURRENT FOCAL SEIZURES AT BIRTH

A Sharma, D Jayachandran, D Agrawal. Paediatrics, Darlington Memorial Hospital, Darlington, UK

10.1136/archdischild-2020-rcpch.43

Case A term baby with no antenatal risk factors was born by emergency caesarean section due to unexplained fetal tachycardia. The pregnancy was uneventful and no resuscitation was required. The baby developed right sided focal seizures at 2 hours of birth (lasted for approximately 2 minutes). Subsequently, she had multiple clusters and prolonged seizures between 2 and 24 hours of birth. The seizures continued after a maximum loading dose of Phenobarbitone (40 mg/kg/dose) and so was given a loading dose of Levetiracetam at 20 mg/kg/dose with good effect. Magnetic Resonance Imaging of the head was performed at 23 hours and the diffusion weighted imaging demonstrated diffusion restriction of left parieto-occipital lobe with corresponding drop on apparent diffusion coefficient mapping in keeping with left cerebral acute infarct. Haematological workup showed Low Protein C and Low Free Protein S which would be repeated at 6 months.

Discussion PAIS are cerebrovascular events secondary to arteriopathic, cardiac and haematological pathology, occurring between 20 weeks of fetal life through to the 28th postnatal day. Most commonly, this involves the middle cerebral artery territory. MR with Diffusion Weighted imaging is the radiologic investigation of choice. Maternal conditions that have been associated with perinatal stroke in the fetus include prothrombotic disorders, cocaine abuse, placental complications and placental vasculopathy. In many cases, the placenta is suspected to be the underlying embolic source for perinatal stroke, although data on placental pathology is often lacking. During the delivery process, an infant may develop a cervical arterial dissection that leads to stroke. Several conditions in the neonatal period predispose to perinatal stroke including prothrombotic disorders, congenital heart disease, meningitis and systemic infection. The outcome is variable and depends on severity, anatomic localization, and other factors. Intravenous Levetiracetam is effective in controlling seizures and could be used as a second line anticonvulsant.

Conclusion Arterial ischemic infarction occurring around the time of birth is an increasingly recognized cause of neurologic disability in children and should therefore be considered as an important differential diagnosis in newborns presenting with focal neonatal seizures.

**G58(P)** DEFINING CEREBRAL PALSY- CONSENSUS OR CONTROVERSY?


10.1136/archdischild-2020-rcpch.44

Introduction Cerebral Palsy (CP) is a well-recognised neurodevelopmental disorder beginning in early childhood and persisting through life. CP registries from developed countries suggest its prevalence is 2–3 per 1000 live births. It has consistently proven a challenge to define CP, as documented by the numerous attempts. This review aimed to investigate both the consensus and controversy surrounding the definition of CP and to investigate which definition is currently the mostly widely accepted and applied.

Methods A literature search was conducted using EMBASE, CINAHL and SCOPUS. The search was limited to articles available in English and peer-reviewed journals. Articles were screened in four stages by two independent reviewers and the Preferred Reporting Items for Systematic Reviews (PRISMA) was used.

Results 375 articles were identified, and 41 full-text articles were included in the study. The literature outlined numerous definitions of CP. Most recently, a new consensus definition was proposed by Rosenbaum et al. which emerged from an international workshop on the definition and classification of CP, held in Maryland, July 2004. However, while widely accepted, this definition still faces criticism.

Conclusions Overall, there has been a marked evolution from the first definition of CP by Little to the current consensus definition of Rosenbaum et al. Use of epidemiological data collected by CP registers and modern diagnostic techniques has paved the way for adjustments of previously scrutinised definitions. However, there is a need for a worldwide consensus to maintain a high accuracy rate of diagnosis and management.

**G59(P)** THE ROLE OF FLUORODEOXYGLUCOSE POSITRON EMISSION TOMOGRAPHY FDG-PET SCAN IN THE DIAGNOSIS OF AUTOIMMUNE ENCEPHALITIS

AJ Jalal, AJ Jollands. Paediatrics, Ninewells Hospital, Dundee, UK

10.1136/archdischild-2020-rcpch.45

The diagnosis of autoimmune encephalitis (AE) is based on clinical features and associated findings on MRI, EEG, CSF examination and neuronal antibody testing. Diagnosis may be difficult when presenting features are atypical and special investigations normal. Additionally neuronal antibody testing is not routinely available which may delay treatment. Fluorodeoxyglucose positron emission tomography scan (FDG-PET) may be an adjunct to aid the diagnosis of early disease and monitor the response to treatment. This literature review aims to establish if there are characteristic FDG-PET features associated with AE and/or specific patterns associated with neuronal antibody types in the first instance and secondly determine if serial FDG-PET can be used to measure response to treatment.

A total of 217 adults and children with suspected or definite AE were identified in the literature. Fifty patients had normal MRI findings but abnormal FDG-PET uptake patterns at diagnosis. Additionally 10 patients with seronegative AE had abnormal diagnostic FDG-PET findings. Serial FDG-PET data were available In 37 patients. Thirteen patients showed improvement and an additional 12 showed complete resolution after treatment which correlated with clinical improvement. There were no specific FDG-PET uptake patterns associated with acute, semi-acute or late phases of the disease however basal ganglia involvement was more commonly seen in those with ion channels and other cell surface protein
antibodies (LGII, CASPR2, DPPX, MOG, Aquaporin4, GQ1b, DPPX, MOG, Aquaporin4, and GQ1b) as opposed to intracellular antibodies.

In conclusion, FDG-PET may provide additional supportive data to aid early diagnosis of AE especially in the context of normal MRI imaging or negative antibody testing. It may also prove useful in monitoring the effect of treatment.

**Abstract G60(P)**

**RED FLAGS: PARENT-REPORTED EARLIEST CONCERNS REGARDING THEIR CHILD’S EMERGING CEREBRAL PALSY**

1 J Baggaley, 1 T Rapley, 1, 3 A Basu. 1 Institute of Health and Society, Newcastle University, Newcastle Upon Tyne, UK; 2Department of Social Work, Education and Community Wellbeing, Northumbria University, Newcastle Upon Tyne, UK; 3Department of Paediatric Neurology, Great North Children’s Hospital, Newcastle Upon Tyne, UK

**Background**

Each year around 1800 UK children are diagnosed with Cerebral Palsy (CP). Of these, 40–50% are deemed ‘low risk’ at birth and therefore rely on their parents and primary care health professionals (HCPs) to identify concerning features and seek early referral. Some parents report difficulties in communicating their concerns, and being falsely reassured.

**Aims**

To describe the nature of the earliest concerns parents report to HCPs in children with emerging CP.

**Methods**

Parents of children with CP were recruited via social media to take part in an, ethically approved, online survey. This collected information on child and respondent demographics and the earliest concerns parents had regarding their child’s development. Thematic analysis was undertaken on the first 200 responses.

**Results**

Four responses were excluded due to ineligibility. Most responses (n=186) were from mothers. Children with Hemiplegic CP made up 51.5% of the sample (table 1). Eight main themes emerged; Developmental Milestones (n=141), Atypical Movements (‘His left leg did not kick excitedly in the bath’) (n=97), Worrying Birth History (n=86), Posture (n=69), Tone (n=48), Feeding (n=23), Temperament (including sleep) (n=22), and Parental Intuition (‘I just knew something wasn’t right.’) (n=16).

**Conclusion/Discussion**

Developmental Milestones were the most frequently reported concern, supporting current screening processes. However, this represented only 28% of the total concern burden. Although some concerns were non-specific, a proportion of concerns in all categories were not acted on.

**Abstract G61(P)**

**WHAT SHOULD TRUSTS CHARGE NHS ENGLAND TO DELIVER SPECIALIST INPATIENT NEUROREHABILITATION IN THE SETTING OF A REGIONAL PAEDIATRIC NEUROSCIENCE CENTRE?**

1 PM Sharpley, 2 L Shuya, 3 A Spray, 4 HK Smith. 1 Bristol Royal Hospital for Children, UHBT, Bristol, UK; 2CORMSS team, University of Southampton, Southampton, UK

**Background**

Each year around 1800 UK children are diagnosed with Cerebral Palsy (CP). Of these, 40–50% are deemed ‘low risk’ at birth and therefore rely on their parents and primary care health professionals (HCPs) to identify concerning features and seek early referral. Some parents report difficulties in communicating their concerns, and being falsely reassured.

**Aims**

To calculate what bed-day tariff a paediatric Regional Neuroscience Centre (RNSC) should charge to deliver a quality, sustainable specialist in-patient neurorehabilitation service, taking into account patient complexity/dependency.

**Methods**

Ethical approval was obtained from University of Southampton. Anonymized data on children receiving in-patient neurorehabilitation at a paediatric RNSC 1/6/2017–31/5/2019 were analyzed. Patient dependency and rehabilitation complexity was assessed by Rehabilitation Complexity Scale (RCS); this provides an overall measure of Care or Risk, Nursing, Therapy, Medical and Equipment needs. RCS-Extended (version-13) was scored for neurorehabilitation patients jointly by multi-disciplinary team members at weekly clinical meetings. RCS-E scores were categorized as: very low level of rehabilitation need (0–4); low level (5–8); medium level (9–12); high level (13–16); very high level (17–22). Discrete-Event Simulation (DES) was used to simulate in-patient neurorehabilitation service work flow, calculating how many patients would be treated each day and their changing rehabilitation needs. Staffing numbers required were based on the modelling results, applying published minimum staffing provisions for adult neurorehabilitation centers. Service costs and bed-day tariffs were calculated from calculated staff numbers, assuming 25% overheads.

**Results**

The database contained 114 children who received inpatient neurorehabilitation over the two-year study period. 21 had no RCS data; 29 others were admitted before the study period, 4 discharged afterwards. Excluding these patients, 69 were used in the model, which mapped routes between dependency levels. Modelling showed 91 patients to be admitted and discharged by the neurorehabilitation service over two years (95% CI 175–107). Mean Length of Stay=53 days (95% CI 44–62). Mean number of beds occupied at any one time by neurorehabilitation in-patients=6.3 (95% CI 4.8-8.0). Of these, 0.65 (95% CI 0.17–1.26) were occupied by patients with very high needs; 1.73 (CI 1.08–2.45) high needs; 2.25 (CI 1.58–2.91) medium needs; 0.20 (CI 0.13–0.28) low needs; 0.08 (CI 0.02–0.17) very low needs. Applying differential published adult staffing standards to the modelled complexity/dependency levels and assuming 25% overheads, the bed-day tariff required to support the specialist neurorehabilitation in-patient service ranged from £622.45–£754.75.

**Conclusions**

Application of simulation modelling to real-world paediatric data suggests costs in keeping with those charged by adult centers.